Skip to content
Sectors How it works Pricing Client stories

Insights

Companies Live signals Events Markets Trends Company lists
Log in
Platform Signal Tracker API Radar Book a 7-day Readout
EirGenix, Inc. logo — Clients'​ Success Is Our Priority

EirGenix, Inc.

Clients'​ Success Is Our Priority

Founded 2012 Taiwan Taiwan 220 employees Post-IPO Equity Health Care, Manufacturing

General Information

Company Name EirGenix, Inc.
Founded Year 2012
Location Taiwan Taiwan
Employees 220
Industries Health Care, Manufacturing
Funding Stage Post-IPO Equity
Social

BounceWatch is an independent company data service, not affiliated with EirGenix, Inc.. To contact EirGenix, Inc., visit eirgenix.com.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

How does EirGenix, Inc. compare?

A PDF of EirGenix, Inc. and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.

See a sample report

This takes a few seconds: we look beyond our own index too.

Meeting EirGenix, Inc. soon?

A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample

About EirGenix, Inc.

EirGenix, Inc. is a Taiwan-based contract development and manufacturing organization focusing on providing high-quality and cost-effective services in the field of biopharmaceuticals. Established in 2012, the company's slogan "Clients'​ Success Is Our Priority" reflects its commitment to client satisfaction. EirGenix offers a range of services including cell line development, process optimization, analytical services, and quality control, with a specialization in biosimilars and antibody-drug conjugate (ADC) development and manufacturing. Notably, the company has received approvals from regulatory bodies such as the Taiwan FDA and Japan PMDA, while awaiting inspections from the U.S. FDA (June 2022) and EMA (2022-2023). In a recent development, EirGenix secured a significant Post-IPO Equity investment on 15 August 2022, with the investment coming from Taiwania Capital Management Corporation. This investment is indicative of the company's potential for growth and its attractiveness to investors within the Health Care and Manufacturing industries. EirGenix's strategic location in Taiwan, a hub for the healthcare and biotechnology sectors, positions it favorably for further expansion and collaboration in the global market.

Business keywords: biopharmaceuticals, contract development, manufacturing organization, biologics, biosimilars, cell line development, process development, analytical services, cGMP manufacturing, antibody-drug conjugate, FDA inspected/approved, Taiwan FDA

Funding Rounds & Investors (3)

View All
Funding Stage Amount Investors Lead Investors Date
Post IPO Equity Undisclosed 1
Taiwania Capital Management Corporation
Taiwania Capital Management Corporation
15 Aug 2022
Post IPO Equity Undisclosed 1
Taiwania Capital Management Corporation
Taiwania Capital Management Corporation
15 May 2020
Post IPO Equity Undisclosed 1
Taiwania Capital Management Corporation
Taiwania Capital Management Corporation
31 Oct 2018

EirGenix, Inc. Alternatives & Competitors

View All Alternatives
EirGenix, Inc. vs
IDT Biologika
IDT Biologika Germany

Your full-service CDMO for viral vaccines, cell & gene therapeutics and other biologics protecting h...

502 employees
Health Care, Manufacturing
EirGenix, Inc. vs
Samsung Biologics
Samsung Biologics Korea South

Innovation, passion and an unwavering dedication to find breakthrough solutions in biomedicines.

2398 employees
Biotechnology, Health Care
EirGenix, Inc. vs
Cognate BioServices, a Charles River Company
Cognate BioServices, a Charles River Company United States

Your CDMO Partner from Concept to Commercial for Cell & Gene Therapy Products

Series B
81 employees
Biotechnology, Health Care
View all alternatives

FAQ About EirGenix, Inc.

Clients'​ Success Is Our Priority
EirGenix, Inc. was founded in 2012.
EirGenix, Inc. is headquartered in Taiwan.
EirGenix, Inc. operates in Health Care and Manufacturing. Its work centres on biopharmaceuticals, contract development, manufacturing organization and biologics.
EirGenix, Inc. has approximately 220 employees.
EirGenix, Inc. has completed 3 funding rounds. The latest funding stage is Post-IPO Equity.
Top alternatives and competitors to EirGenix, Inc. include IDT Biologika, Samsung Biologics, Cognate BioServices, a Charles River Company, BioSpring GmbH, Pii (Pharmaceutics International, Inc.). These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
EirGenix, Inc. and IDT Biologika are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for EirGenix, Inc., https://bouncewatch.com/company/eirgenix-inc, updated 5 January 2025. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Talk to an analyst Book a 7-day Readout